The Committee for Medicinal Products for Human Use (CHMP) concluded that the data provided by the Company have shown that, used at a dose that is calculated as recommended, ATryn, can bring the antithrombin activity levels to an acceptable level in non-pregnant patients with congenital antithrombin deficiency undergoing surgery.